Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. / Jacobson, Glenn A; Hostrup, Morten; Narkowicz, Christian K; Nichols, David S; Walters, E Haydn.
I: Drug Testing and Analysis, Bind 11, Nr. 7, 2019, s. 950-956.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control
AU - Jacobson, Glenn A
AU - Hostrup, Morten
AU - Narkowicz, Christian K
AU - Nichols, David S
AU - Walters, E Haydn
N1 - CURIS 2019 NEXS 132 This article is protected by copyright. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Formoterol is a long-acting beta2-adrenoceptor agonist (LABA) used for treatment of asthma and exercise-induced bronchoconstriction. Formoterol is usually administered as a racemic (rac-) mixture of (R,R)- and (S,S)-enantiomers. While formoterol is restricted by the World Anti-Doping Agency (WADA), inhalation of formoterol is permitted to a predetermined dose (54 μg/24 hours) and a urine threshold of 40 ng/mL. However, chiral switch enantiopure (R,R)-formoterol is available, effectively doubling the therapeutic advantage for the same threshold. The aim of this study was to investigate whether formoterol exhibits enantioselective urinary pharmacokinetics following inhalation. Six healthy volunteers were administered a 12 μg inhaled dose of rac-formoterol. Urine was collected over 24-hours and analysed by enantioselective UPLC-MS/MS assay. Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96(1.05-13.4) ng/mL, 1.67(0.16-9.67) ng/mL, 0.45(0.16-1.51) ng/mL, 0.61(0.33-0.78) ng/mL, and 0.17(0.08-1.06) ng/mL at 2, 4, 8, 12 and 24 hours, respectively, well below the 2019 urine threshold. The proportion of conjugation differed between enantiomers with glucuronide conjugation much greater for (R,R)-formoterol (around 30-60% of total) compared to (S,S)-formoterol (0-30%). There was clear evidence of inter-individual enantioselectivity observed in the ratios of (R,R):(S,S)-formoterol, where (S,S)- was predominant in free formoterol, and (R,R)- predominant in the conjugated metabolite. In conclusion, rac-formoterol delivered by inhalation exhibits enantioselective elimination in urine following single dose administration. Enantioselective assays should be employed in doping control to screen for banned beta2-agonist chiral switch products such as (R,R)-formoterol, and total hydrolysed rac-formoterol is warranted to account for inter-individual differences in enantioselective glucuronidation.
AB - Formoterol is a long-acting beta2-adrenoceptor agonist (LABA) used for treatment of asthma and exercise-induced bronchoconstriction. Formoterol is usually administered as a racemic (rac-) mixture of (R,R)- and (S,S)-enantiomers. While formoterol is restricted by the World Anti-Doping Agency (WADA), inhalation of formoterol is permitted to a predetermined dose (54 μg/24 hours) and a urine threshold of 40 ng/mL. However, chiral switch enantiopure (R,R)-formoterol is available, effectively doubling the therapeutic advantage for the same threshold. The aim of this study was to investigate whether formoterol exhibits enantioselective urinary pharmacokinetics following inhalation. Six healthy volunteers were administered a 12 μg inhaled dose of rac-formoterol. Urine was collected over 24-hours and analysed by enantioselective UPLC-MS/MS assay. Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96(1.05-13.4) ng/mL, 1.67(0.16-9.67) ng/mL, 0.45(0.16-1.51) ng/mL, 0.61(0.33-0.78) ng/mL, and 0.17(0.08-1.06) ng/mL at 2, 4, 8, 12 and 24 hours, respectively, well below the 2019 urine threshold. The proportion of conjugation differed between enantiomers with glucuronide conjugation much greater for (R,R)-formoterol (around 30-60% of total) compared to (S,S)-formoterol (0-30%). There was clear evidence of inter-individual enantioselectivity observed in the ratios of (R,R):(S,S)-formoterol, where (S,S)- was predominant in free formoterol, and (R,R)- predominant in the conjugated metabolite. In conclusion, rac-formoterol delivered by inhalation exhibits enantioselective elimination in urine following single dose administration. Enantioselective assays should be employed in doping control to screen for banned beta2-agonist chiral switch products such as (R,R)-formoterol, and total hydrolysed rac-formoterol is warranted to account for inter-individual differences in enantioselective glucuronidation.
KW - Faculty of Science
KW - Arformoterol
KW - Enantiomer
KW - ADME
KW - Metabolism
KW - SABA
KW - Beta2-agonist
U2 - 10.1002/dta.2587
DO - 10.1002/dta.2587
M3 - Journal article
C2 - 30865387
VL - 11
SP - 950
EP - 956
JO - Drug Testing and Analysis
JF - Drug Testing and Analysis
SN - 1942-7603
IS - 7
ER -
ID: 214868385